Effect of immunocheckpoint inhibitor combined with ranvartinib on TACE resistance to advanced primary liver cancer and its influence on serum PDGF and VEGF

Di Liang; Guo Qingliang; Duan Binwei; Zhao Xiaofei; Ding Jing

doi:10.3969/j.issn.1671-6450.2023.01.010

Home>Articles>Effect of immunocheckpoint inhibitor combined with ranvartinib on TACE resistance to advanced primary liver cancer and its influence on serum PDGF and VEGF

DOI: 10.3969/j.issn.1671-6450.2023.01.010

Effect of immunocheckpoint inhibitor combined with ranvartinib on TACE resistance to advanced primary liver cancer and its influence on serum PDGF and VEGF

Di Liang

Guo Qingliang

Duan Binwei

Zhao Xiaofei

Ding Jing

Machine-generated Keywords：

Publication Date：2023-01-18

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 54-59 )

Chinese Journal of Difficult and Complicated Cases

ISTIC

ISSN：1671-6450

Year, Vol.(Issue)：2023,22(1)